SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China

Published:2017-03-23 Issue:1 Volume:14 Page:
ISSN:1743-422X
Container-title:Virology Journal
language:en
Short-container-title:Virol J

Author:

Li Yanhua,Wang Jiuping,Wang Juan,Xiao Yunfeng,Xu Bin,Li Hongwei,Yang Liu,Hao Xiaoke,Ma Yueyun

Funder

National instruments major projects of China

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Virology

Link

http://link.springer.com/content/pdf/10.1186/s12985-017-0708-6.pdf

Reference31 articles.

1. Antonelli A, Pistello M. New Therapies, Markers and Therapeutic Targets in HCV Chronic Infection, and HCV Extrahepatic Manifestations. Curr Drug Targets. 2015.

2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–57.

3. Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, et al. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterol. 2012;12:162.

4. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.

5. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–23.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study;Medicine;2024-02-16

2. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China;Frontiers in Public Health;2021-12-09

3. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection;Annals of Palliative Medicine;2021-10

4. WITHDRAWN: Analysis of host genetic variations associated with response to anti-HCV therapies in global populations;Meta Gene;2021-03

5. A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan;Current Medical Research and Opinion;2021-01-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3